Drug Approval | September 03, 2024
Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
e brings over 27+ years of rich pharmaceutical experience
Subscribe To Our Newsletter & Stay Updated
